<div id="readability-page-1"><p>Celldex Therapeutics, Inc. (NASDAQ:CLDX - Get Free Report)'s stock price hit a new 52-week high during mid-day trading on Thursday . The stock traded as high as $29.40 and last traded at $29.4580, with a volume of 176251 shares changing hands. The stock had previously closed at $27.81.</p><div><p><span></span><span>Get <strong>Celldex Therapeutics</strong> alerts:</span></p></div><h2>Wall Street Analyst Weigh In</h2><p>Several research analysts have recently weighed in on CLDX shares. Barclays decreased their target price on shares of Celldex Therapeutics from $25.00 to $21.00 and set an &#34;underweight&#34; rating for the company in a research note on Tuesday, November 11th. HC Wainwright reduced their price target on Celldex Therapeutics from $50.00 to $42.00 and set a &#34;buy&#34; rating for the company in a report on Wednesday, August 20th. Weiss Ratings  restated a &#34;sell (d-)&#34; rating on shares of Celldex Therapeutics in a report on Wednesday, October 8th. Citigroup decreased their price target on shares of Celldex Therapeutics from $56.00 to $48.00 and set a &#34;buy&#34; rating for the company in a research report on Wednesday, August 20th. Finally, Mizuho assumed coverage on shares of Celldex Therapeutics in a report on Tuesday, October 21st. They issued an &#34;outperform&#34; rating and a $48.00 price target on the stock. One investment analyst  has rated the stock with a Strong Buy rating, seven have given a Buy rating, one  has assigned  a Hold rating and two have issued  a Sell rating to the company's stock. According to data from MarketBeat, the company  has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $43.80.</p><p><b>Get Our Latest Analysis on CLDX</b></p><h2>Celldex Therapeutics Trading Up 5.2%</h2><p>The stock's 50-day moving average price is $25.96 and its 200-day moving average price is $23.45. The company has a market capitalization of $1.94 billion, a P/E ratio of -8.68 and a beta of 1.13. </p><p>Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last released its earnings results on Monday, November 10th. The biopharmaceutical company reported ($1.01) earnings per share for the quarter, missing analysts' consensus estimates of ($0.88) by ($0.13). Celldex Therapeutics had a negative return on equity of 33.22% and a negative net margin of 3,446.88%. Sell-side analysts expect that  Celldex Therapeutics, Inc. will post -2.48 earnings per share for the current fiscal year. </p><h2>Insider Transactions at Celldex Therapeutics</h2><p>In other Celldex Therapeutics news, insider Richard M. Wright sold 49,298 shares of Celldex Therapeutics stock in a transaction dated Thursday, November 13th. The stock was sold at an average price of $24.00, for a total transaction of $1,183,152.00. Following the transaction, the insider owned 20,833 shares of the company's stock, valued at $499,992. The trade was a 70.29% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Corporate insiders own  4.40% of the company's stock. </p><h2>Institutional Trading of Celldex Therapeutics</h2><p>Several large investors have recently added to or reduced their stakes in CLDX. Handelsbanken Fonder AB grew its position in  Celldex Therapeutics by 2.4% in the 2nd quarter. Handelsbanken Fonder AB now owns 21,600 shares of the biopharmaceutical company's stock worth $440,000 after purchasing an additional 500 shares during the last quarter.  Russell Investments Group Ltd. raised its holdings in  Celldex Therapeutics by 27.6% in the 2nd quarter. Russell Investments Group Ltd. now owns 2,315 shares of the biopharmaceutical company's stock valued at $47,000 after acquiring an additional 501 shares in the last quarter.  MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of  Celldex Therapeutics by 1.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,451 shares of the biopharmaceutical company's stock worth $798,000 after acquiring an additional 680 shares during the period.  AlphaQuest LLC increased its position in shares of  Celldex Therapeutics by 7.0% during the second quarter. AlphaQuest LLC now owns 12,956 shares of the biopharmaceutical company's stock valued at $264,000 after purchasing an additional 844 shares during the period.  Finally, Nisa Investment Advisors LLC raised its stake in shares of  Celldex Therapeutics by 171.7% in the second quarter. Nisa Investment Advisors LLC now owns 1,394 shares of the biopharmaceutical company's stock valued at $28,000 after purchasing an additional 881 shares in the last quarter. </p><h2>Celldex Therapeutics Company Profile</h2> (Get Free Report)<p>Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.</p><h2>Recommended Stories</h2><ul><li>Five stocks we like better than Celldex Therapeutics</li><li>What Are the FAANG Stocks and Are They Good Investments?</li><li>Wolfspeed Just Got a $698 Million Lifeline—Here’s Why That Changes Everything</li><li>10 Best Airline Stocks to Buy</li><li>Uber Gets a Street-High Upgrade as Robotaxis Roll Out in Dallas</li><li>Trading Stocks: RSI and Why it's Useful</li><li>Investors Were Dead Wrong About Box—This AI-Driven Comeback Just Proved It</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Celldex Therapeutics Right Now?</h2><p>Before you consider Celldex Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Celldex Therapeutics wasn't on the list.</p><p>While Celldex Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

CLDX

<p>Celldex Therapeutics (NASDAQ:CLDX) reached a new 52-week high, trading at $29.4580. Analysts have mixed ratings, with a consensus target price of $43.80. The company reported a quarterly loss, missing estimates. Insider Richard M. Wright sold shares, reducing his position by 70.29%. Institutional investors adjusted their stakes in the company. Celldex develops therapeutic antibodies for various diseases.</p>

Celldex Therapeutics (NASDAQ:CLDX) Reaches New 12-Month High - Here's Why